Kashim RM, Newton P, Ojo O. Diabetic Retinopathy Screening a Systematic Review on Patients’ Non-Attendance. Int J Environ Res Public Health. 2018;15(1):157.
Article
PubMed Central
Google Scholar
Feldman-Billard S, Larger E, Massin P. Stand Screening Surveillance O Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44(1):4–14.
Article
CAS
PubMed
Google Scholar
Platania CBM, Maisto R, Trotta MC, D’Amico M, Rossi S, Gesualdo C, et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. Br J Pharmacol. 2019;176(13):2179–94.
CAS
PubMed
PubMed Central
Google Scholar
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Global Health. 2017;5(12):E1221–34.
Article
PubMed
Google Scholar
Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012;35(3):556–64.
Article
PubMed
PubMed Central
Google Scholar
Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Experiment Ophthalmol. 2016;44(4):260–77.
Article
PubMed
Google Scholar
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.
Article
PubMed
Google Scholar
P S, J Y, KY C, E T, health RIJJog. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. 2018;8(1):010803.
Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diab Investigation.
Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. Ophthalmologica. 2020;243(1):9–20.
Article
CAS
PubMed
Google Scholar
Rajalakshmi R, Prathiba V, Arulmalar S, Usha M. Review of retinal cameras for global coverage of diabetic retinopathy screening. Eye. 2021;35(1):162–72.
Article
PubMed
Google Scholar
Xie YC, Nguyen QD, Hamzah H, Lim G, Bellemo V, Gunasekeran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digital Health. 2020;2(5):E240–9.
Article
PubMed
Google Scholar
Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA. 2017;318(22):2211–23.
Article
PubMed
PubMed Central
Google Scholar
Dismuke C. Progress in examining cost-effectiveness of AI in diabetic retinopathy screening. Lancet Digital Health. 2020;2(5):E212–3.
Article
PubMed
Google Scholar
He J, Cao TY, Xu FP, Wang SS, Tao HQ, Wu T, et al. Artificial intelligence-based screening for diabetic retinopathy at community hospital. Eye. 2020;34(3):572–6.
Article
PubMed
Google Scholar
Li ZX, Zhang J, Fong N, He MG. Using artificial intelligence as an initial triage strategy in diabetic retinopathy screening program in China. Zhonghua Yi Xue Za Zhi. 2020;100(48):3835–40.
CAS
PubMed
Google Scholar
Ming S, Xie K, Lei X, Yang Y, Zhao Z, Li S, et al. Evaluation of a novel artificial intelligence-based screening system for diabetic retinopathy in community of China: a real-world study. Int Ophthalmol. 2021;41(4):1291–9.
Article
PubMed
Google Scholar
Shah A, Clarida W, Amelon R, Hernaez-Ortega MC, Navea A, Morales-Olivas J, et al. Validation of Automated Screening for Referable Diabetic Retinopathy With an Autonomous Diagnostic Artificial Intelligence System in a Spanish Population. J Diabetes Sci Technol. 2021;15(3):655–63.
Article
PubMed
Google Scholar
Bhaskaranand M, Ramachandra C, Bhat S, Cuadros J, Nittala MG, Sadda SR, et al. The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes. Diabetes Technol Ther. 2019;21(11):635–43.
Article
PubMed
PubMed Central
Google Scholar
Ming S, Xie KP, Lei X, Yang YR, Zhao ZX, Li SY, et al. Evaluation of a novel artificial intelligence-based screening system for diabetic retinopathy in community of China: a real-world study. Int Ophthalmol. 2021;41(4):1291–9.
Article
PubMed
Google Scholar
Li YZ, Teng D, Shi XG, Qin GJ, Qin YF, Quan HB, Prevalence of diabetes recorded in mainland China using, et al. diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ-Brit Med J. 2018;2020:369.
Google Scholar
Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608–22.
Article
PubMed
Google Scholar
He J, Cao T, Xu F, Wang S, Tao H, Wu T, et al. Artificial intelligence-based screening for diabetic retinopathy at community hospital. Eye (Lond). 2020;34(3):572–6.
Article
Google Scholar
Li M, Wang GY, Xia HH, Tang XY, Feng ZQ, et al. Clinical evaluation of artificial intelligence system based on fundus photograph in diabetic retinopathy screening. Chin J Exp Ophthalmol. 2019;37(8):663–8.
Google Scholar
Khalaf SS, Al-Bdour MD, Al-Till MI. Clinical biomicroscopy versus fluorescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy. Eur J Ophthalmol. 2007;17(1):84–8.
Article
CAS
PubMed
Google Scholar
Zhang WJ, Wei M. The evaluation of the mortality and life expectancy of chinese population. Population Journal. 2016;38(03):18–28.
Google Scholar
Tung TH, Chen SJ, Shih HC, Chou P, Li AF, Lee FL, et al. Assessing the natural course of diabetic retinopathy: A population-based study in Kinmen. Taiwan Ophthalmic Epidemiology. 2006;13(5):327–33.
Article
PubMed
Google Scholar
Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124(1 Pt 2):164–9.
Article
CAS
PubMed
Google Scholar
Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA-J Am Med Assoc. 2000;283(7):889–96.
Article
CAS
Google Scholar
Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The Cost-Utility of Telemedicine to Screen for Diabetic Retinopathy in India. Ophthalmology. 2013;120(3):566–73.
Article
PubMed
Google Scholar
Smith DH, Johnson ES, Russell A, Hazlehurst B, Muraki C, Nichols GA, et al. Lower visual acuity predicts worse utility values among patients with type 2 diabetes. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2008;17(10):1277–84.
Article
Google Scholar
Yfantopoulos J, Chantzaras A. Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications. Eur J Health Economics. 2020;21(5):729–43.
Article
Google Scholar
Tang J, Liang Y, O’Neill C, Kee F, Jiang J, Congdon N. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model. Lancet Glob Health. 2019;7(7):E968–78.
Article
PubMed
Google Scholar
Tang J, Liang Y, O’Neill C, Kee F, Jiang J, Congdon N. Cost-effectiveness and cost-utility of population-based glaucoma screening in China a decision-analytic Markov model. Lancet Global Health. 2019;7(7):e968–78.
Article
PubMed
Google Scholar
Zhao Q, Wang L, Tao T, Xu B. Impacts of the “transport subsidy initiative on poor TB patients” in Rural China: a patient-cohort based longitudinal study in rural China. PLoS One. 2013;8(11):e82503.
Article
PubMed
PubMed Central
Google Scholar
Sluiter RL, Janzing JGE, van der Wilt GJ, Kievit W, Teichert M. An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care. Pharmacogenomics J. 2019;19(5):480–9.
Article
CAS
PubMed
Google Scholar
Hutubessy R, Chisholm D, Edejer TT-T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost effectiveness and resource allocation: C/E. 2003;1(1):8.
World Health O, Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, et al. Making choices in health : WHO guide to cost-effectiveness analysis / edited by T. Tan-Torres Edejer ... [et al]. Geneva: World Health Organization; 2003.
Tufail A, Rudisill C, Egan C, Kapetanakis V, Salas-Vega S, Owen C, et al. Automated Diabetic Retinopathy Image Assessment Software: Diagnostic Accuracy and Cost-Effectiveness Compared with Human Graders. Ophthalmology. 2017;124(3):343–51.
Article
PubMed
Google Scholar
Scotland G, McNamee P, Philip S, Fleming A, Goatman K, Prescott G, et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. Bri J Ophthalmol. 2007;91(11):1518–23.
Article
CAS
Google Scholar
Xie Y, Nguyen QD, Hamzah H, Lim G, Bellemo V, Gunasekeran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digital Health. 2020;2(5):E240–9.
Article
PubMed
Google Scholar
Fuller SD, Hu J, Liu JC, Gibson E, Gregory M, Kuo J, et al. Five-Year Cost-Effectiveness Modeling of Primary Care-Based, Nonmydriatic Automated Retinal Image Analysis Screening Among Low-Income Patients with Diabetes. J Diabetes Sci Technol. 2020:1932296820967011.
Thomas RL, Winfield TG, Prettyjohns M, Dunstan FD, Cheung WY, Anderson PM, et al. Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening. Eur J Health Econ. 2020;21(7):993–1002.
Article
PubMed
PubMed Central
Google Scholar
Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, et al. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med. 2017;376(16):1507–16.
Article
PubMed
Google Scholar
Eleuteri A, Fisher AC, Broadbent DM, Garcia-Finana M, Cheyne CP, Wang A, et al. Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia. 2017;60(11):2174–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Scotland G, McKeigue P, Philip S, Leese GP, Olson JA, Looker HC, et al. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. Diabetic Med. 2016;33(7):886–95.
Article
CAS
PubMed
Google Scholar
Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assessment. 2015;19(74):1.
Article
Google Scholar
Lian JX, McGhee SM, Gangwani RA, Chan CKW, Lam CLK, Yap MKH, et al. The impact of a co-payment on the cost- effectiveness of screening for diabetic retinopathy. J Public Health. 2016;38(4):782–92.
Article
Google Scholar